What are the recommended dosing regimens and approved indications for duloxetine?

Duloxetine Dosing and Indications

Duloxetine is FDA-approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain (including chronic low back pain and osteoarthritis), with the standard effective dose being 60 mg once daily for most indications.

FDA-Approved Indications and Dosing

Diabetic Peripheral Neuropathic Pain

• Start: 60 mg once daily 1
• Maximum: 60 mg once daily - Higher doses provide no additional benefit and are less well tolerated 1
• Duration for adequate trial: 4 weeks 2
• For tolerability concerns, consider starting at 30 mg once daily for 1 week before increasing to 60 mg 2
• This is a first-line therapy alongside pregabalin and gabapentin 3

Fibromyalgia

• Start: 30 mg once daily for 1 week 1
• Target: 60 mg once daily 1
• Maximum: 60 mg once daily - Doses above 60 mg show no additional benefit and higher adverse event rates 1
• Some patients respond to the 30 mg starting dose 1

Major Depressive Disorder

• Start: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or 30 mg twice daily) 1
• Alternative start: 30 mg once daily for 1 week, then increase to 60 mg 1
• Maximum studied: 120 mg/day - No evidence that doses >60 mg provide additional benefit 1

Generalized Anxiety Disorder

Adults <65 years:

• Start: 60 mg once daily 1
• Alternative: 30 mg once daily for 1 week, then 60 mg 1
• Maximum studied: 120 mg/day in 30 mg increments if needed 1

Geriatric patients (≥65 years):

• Start: 30 mg once daily for 2 weeks 1
• Target: 60 mg/day 1
• May increase beyond 60 mg in 30 mg increments if needed 1

Pediatric patients (7-17 years):

• Start: 30 mg once daily for 2 weeks 1
• Target range: 30-60 mg once daily 1
• Maximum studied: 120 mg/day 1

Chronic Musculoskeletal Pain (Low Back Pain, Osteoarthritis)

• Start: 30 mg once daily for 1 week 1
• Target: 60 mg once daily 1
• Higher doses show no additional benefit and more adverse events 1

Key Clinical Considerations

Neuropathic Pain Evidence

Duloxetine demonstrates consistent efficacy in diabetic peripheral neuropathy with a Number Needed to Treat (NNT) of approximately 5 for 50% pain reduction 2, 4. The evidence is strongest for painful diabetic neuropathy; efficacy in other neuropathic pain conditions is less well established 2.

Dosing Principles

• 60 mg once daily is as effective as 60 mg twice daily 2
• Nausea is the most common adverse effect, reduced by starting at 30 mg for 1 week 2, 5
• Pain relief can occur within 1 week of reaching therapeutic dose 1
• No clinically significant ECG or blood pressure changes at therapeutic doses 2

Special Populations

• Avoid in chronic liver disease or cirrhosis 1
• Avoid in severe renal impairment (GFR <30 mL/min) 1
• Consider lower starting dose and gradual titration in diabetic patients with renal impairment 1
• Adverse events may be more severe in older adults but can be attenuated with lower doses and slower titration 3

Discontinuation

Taper gradually rather than abrupt cessation to minimize discontinuation symptoms including dizziness, headache, nausea, paresthesia, and irritability 1.

Drug Interactions

• Contraindicated with MAOIs - Allow 14 days after stopping MAOI before starting duloxetine; allow 5 days after stopping duloxetine before starting MAOI 1
• Avoid with potent CYP1A2 inhibitors 1
• Use caution with drugs metabolized by CYP2D6 1

Comparative Effectiveness

When compared to other first-line agents for neuropathic pain, duloxetine ranks alongside tricyclic antidepressants and calcium channel α2-δ ligands (gabapentin, pregabalin) 2, 3. For fibromyalgia, duloxetine shows moderate efficacy with an NNT of 8 4, 6, which is less robust than for diabetic neuropathy but still clinically meaningful, particularly in patients with comorbid depression or anxiety 7, 6.